Achieving CHRSR reduces the need for RRT and improves survival. Furthermore, patients treated with terlipressin and albumin who achieve CHRSR have a better outcome at Day 90 compared to patients achieving CHRSR with albumin alone. Disclosures: Arun J. Sanyal – Advisory Committees or Review Panels: Bristol Myers, Gilead, Abbott, Ikaria; Consulting: Salix, Immuron, Exhalenz, Nimbus, Genentech, Echosens, Takeda; Grant/Research Support: Salix, Genentech, Genfit, Intercept, Ikaria, Takeda, GalMed, Novartis, Gilead; Independent Contractor: UpToDate, Elsevier Selleck RG7420 Thomas D. Boyer – Consulting: Ikaria; Grant/Research Support: Abbvie, Gilead, Merck R Todd Frederick – Advisory Committees
or Review Panels: Vital Therapies; Consulting: Salix, Gilead, Ocera, Hyperion Fredric Regenstein – Advisory Committees or Review Panels: Gilead, Janssen; Grant/Research Support: Bristol-Myers Squibb, Roche/Genentech, Janssen, Ikaria, Merck; Speaking and Teaching: Salix, Gilead; Stock Shareholder: Johnson & Johnson Lorenzo Rossaro – Consulting: Merck, Genentec; Grant/Research Support: Gilead, Novartis, Vertex, BMS, AbbVie, Jannsen; Speaking and Teaching: Salix, Onix/Bayer Victor Araya – Advisory Committees or Review Panels: Gilead, AbbVie; Dasatinib cost Grant/ Research Support: Vertex, Abbvie, Merck, Orphan Therapeautics, Johnson & Johnson, Bristol Myers Squibb; Speaking
and Teaching: AbbVie, Gilead, Bristol Myers Squib, Onyx Hugo E. Vargas – Advisory Committees or Review Panels: Eisai; Grant/Research Support: Merck, Gilead, Idenix, Novartis, Vertex, Janssen, Bristol Myers, Ikaria, AbbVie
K. Rajender Reddy – Advisory Committees or Review Panels: Genentech-Roche, Merck, Janssen, Vertex, Gilead, BMS, Novartis, Abbvie; Grant/Research Support: Merck, BMS, Ikaria, Gilead, Janssen, AbbVie Khurram Jamil – Employment: IKARIA; Stock Shareholder: IKARIA Stephen Chris Pappas – Consulting: Orphan Therapeutics, Abbvie Background: It is well established that conventional glomerular filtration rate (GFR) equations underestimate the extent of kidney dysfunction in patients with cirrhosis. The objective of our study was to assess the performance of novel GFR-estimating equations in subjects with cirrhosis. Methods: Between 2010 and 2014, we measured GFR in 91 subjects medchemexpress with cirrhosis by iothalamate plasma clearance simultaneously with serum Cr, cystatin C, beta-trace protein, and beta-2 microglobulin. Multivariate linear regression analysis was performed to develop GFR-estimating models. Performance of the novel prediction models, CrCl, estimated CrCl (eCrCl), and conventional GFR-estimating equations was quantified as the percentage of GFR estimates that differed by greater than 30% (1-P30) or 20% of measured GFR (mGFR) (1-P20) or the root mean square error (RMSE). Results: Among 91 subjects with cirrhosis, female gender was an independent predictor of serum Cr (β=−0.19, P=0.